TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Perseus Proteomics, Inc. ( (JP:4882) ) just unveiled an announcement.
Perseus Proteomics Inc. has announced an amendment regarding its PPMX-T003 project, which is part of a drug discovery support program for orphan drugs. The amendment clarifies that the research group led by Dr. Ai Kotani at Osaka University, rather than Osaka Metropolitan University, has identified PPMX-T003 as a potential therapeutic drug for ANKL. This correction may impact stakeholders’ understanding of the project’s progress and the company’s collaboration with academic institutions.
More about Perseus Proteomics, Inc.
YTD Price Performance: 16.37%
Average Trading Volume: 792,805
Technical Sentiment Consensus Rating: Sell
Current Market Cap: Yen9.64B
Learn more about 4882 stock on TipRanks’ Stock Analysis page.